Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Harrow Health. The associated price target remains the same with $63.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Shrader has given his Buy rating due to a combination of factors that highlight Harrow Health’s strategic positioning and financial maneuvers. The company recently restructured its debt, which involved prepaying a significant amount of outstanding borrowings. This move not only cleaned up the company’s financial story but also led to a notable increase in stock value, reflecting investor confidence.
Additionally, Harrow Health’s acquisition of the remaining equity interest in MELT, a developer of a promising non-opioid pain-relief drug, positions the company for future growth. The management’s reaffirmation of 2025 sales guidance and the growing recognition of Harrow as a key player in the eye-care space further bolster the company’s prospects. These strategic initiatives, combined with a strong distribution network and potential new product additions, underpin Shrader’s positive outlook on Harrow Health.
In another report released yesterday, Craig-Hallum also maintained a Buy rating on the stock with a $64.00 price target.